FOGHORN THERAPEUTICS
Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order.By manipulating this system with our unique Gene Traffic ControlTM platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease.With Gene Traffic ControlTM Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.
FOGHORN THERAPEUTICS
Industry:
Biopharma Biotechnology Health Care Life Science Therapeutics
Founded:
2015-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.foghorntx.com
Total Employee:
51+
Status:
Active
Contact:
617-586-3100
Total Funding:
111 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Sitelinks Search Box Euro Microsoft Exchange Online
Similar Organizations
EPIX Therapeutics
EPIX Therapeutics develops and commercializes microwave radiometry-based products for electrophysiology tests.
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
Ally Therapeutics
Ally Therapeutics solves the immune response barriers for gene therapy.
Ambrx
Ambrx develops protein therapeutics that preserve potency, reduce dosing frequency, and improve homogeneity of the drug substance.
Autobahn Therapeutics
Autobahn Therapeutics is a developer of regenerative medicines to restore hope for people affected by CNS disorders.
BeneVir Biopharm
Maryland startup BeneVir is developing immunotherapy viruses that rid the body of two types of tumor cells.
Bicara Therapeutics
Bicara Therapeutics develops dual-action cancer therapies, combining targeted treatments with tumor modulators for enhanced impact.
Bioline AgroSciences
Bioline produces and markets a wide range of invertebrate biological control organisms which are used for control of insect pests.
Bionaut Labs
Bionaut Labs revolutionizes the treatment of central nervous system disorders with its precision medicine treatment modality.
CDx Diagnostics
CDx Diagnostics develops and provides diagnostic systems intended to prevent cancer by detecting pre-cancerous cells.
FoxBio
FoxBio is a Company that will develop Antoxerene’s collection of small molecules that target senescent cells.
Fulcrum Therapeutics
Fulcrum Therapeutics is a biotechnology company that develops new medicines to treat patients with rare genetic diseases.
Ginkgo Bioworks
Ginkgo Bioworks is a developer of biological engineering products and custom microbes across multiple markets.
HotSpot Therapeutics
HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment.
Iconic Therapeutics
Iconic Therapeutics develops and commercializes immunoconjugate proteins that trigger the immune system to destroy invader cells.
ImCheck Therapeutics
ImCheck Therapeutics is a developing novel therapeutics that target members of the butyrophilin (BTN) super-family of checkpoint molecules.
Jounce Therapeutics
Jounce Therapeutics is developing cancer immune-therapies to harness the immune system to attack cancerous cells and tumors.
LNC Therapeutics
LNC Therapeutics is developing gut microbiota directed drugs to target obesity and associated cardiometabolic diseases.
Metabolic Solutions Development
Metabolic Solutions Development develops innovative therapeutics based on a novel pharmacological method to treat type two diabetes.
Nereid Therapeutics
Nereid Therapeutics is discovering new disease treatments by applying research and technologies in biomolecular condensates.
OncoHealth
OncoHealth designs screening devices that detects and diagnoses cancer.
Tenaya Therapeutics
Tenaya Therapeutics is a developer of novel therapies designed to offer treatment for heart disease.
Tissue Genesis
Tissue Genesis is an innovator of advanced tissue engineering and cell therapy solutions.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Advisors List
Board_member
2016-06-01
Current Employees Featured
Igor Sill Seed Investor @ Foghorn Therapeutics
Seed Investor
2016-01-01
Carl Decicco Chief Scientific Officer @ Foghorn Therapeutics
Chief Scientific Officer
2018-12-01
Carl P. Decicco Chief Scientific Officer @ Foghorn Therapeutics
Chief Scientific Officer
Steven Bellon Chief Scientific Officer @ Foghorn Therapeutics
Chief Scientific Officer
2022-01-01
Samuel Agresta Chief Medical Officer @ Foghorn Therapeutics
Chief Medical Officer
Cigall Kadoch Scientific Founder @ Foghorn Therapeutics
Scientific Founder
2016-03-01
Adrian Gottschalk CEO @ Foghorn Therapeutics
CEO
2017-05-01
Allan Reine Chief Financial Officer @ Foghorn Therapeutics
Chief Financial Officer
Founder
Stock Details
Investors List
Irving Investors
Irving Investors investment in Venture Round - Foghorn Therapeutics
Invus
Invus investment in Venture Round - Foghorn Therapeutics
Casdin Capital
Casdin Capital investment in Venture Round - Foghorn Therapeutics
Flagship Pioneering
Flagship Pioneering investment in Venture Round - Foghorn Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-01-10 | Foghorn Therapeutics Announces Chief Scientific Officer Succession |
Official Site Inspections
http://www.foghorntx.com Semrush global rank: 4.12 M Semrush visits lastest month: 2.93 K
Unable to get host informations!!!
Foghorntx.com lookup results from whois.networksolutions.com server:
- Domain created: 17th-Jul-2015
- Domain updated: 31st-Jan-2023
- Domain expires: 17th-Jul-2026 1 Year, 26 Days left
- Website age: 9 Years, 339 Days
- Registrar Domain ID: 1947561462_DOMAIN_COM-VRSN
- Registrar Url: http://networksolutions.com
- Registrar WHOIS Server: whois.networksolutions.com
- Registrar Abuse Contact Email: domain.operations@web.com
- Registrar Abuse Contact Phone: +1.8777228662
- Name server:
- NS51.WORLDNIC.COM
- NS52.WORLDNIC.COM
More informations about "Foghorn Therapeutics"
Foghorn Therapeutics Org Chart + Executive Team - The Official …
Www.foghorntx.com. has 29 executives - and belongs to Flagship Pioneering +1 617 586 3100; Add an executive. Latest news on Foghorn Therapeutics (FHTX) Anything missing? We …See details»
Leadership - foghorntx.com
Before joining Fred Hutch, Dr. Lynch held leadership roles as CSO at Bristol-Myers Squibb, CEO of Massachusetts General Physicians Organization, director of Yale Cancer Center, physician …See details»
Foghorn Therapeutics
Apr 22, 2025 Foghorn Therapeutics was founded in 2016 by world renowned scientists Alexis Borisy and Bruce Booth as a pioneering biopharmaceutical company focused on using gene …See details»
Foghorn Therapeutics CEO and Key Executive Team | Craft.co
Foghorn Therapeutics's Chief Executive Officer is Adrian Gottschalk. Other executives include Samuel Agresta, Chief Medical Officer; Fanny Cavalié, Senior Vice President, Business and …See details»
Foghorn Therapeutics Company Profile | Management and
SQL International Organization for Standardization . C# Microsoft . Python Python Software Foundation . Other Communication and Collaboration Software (4 Technologies) ...See details»
Foghorn Therapeutics - Crunchbase Company Profile
Contact Email info@foghorntx.com Phone Number 617-586-3100 Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order.By manipulating this …See details»
Foghorn Therapeutics Inc. Company Overview, Contact Details ...
May 20, 2024 foghorntx attends event TD Cowen 45th Annual Health Care Conference. Additionally, Foghorn will present at the TD Cowen 45th Annual Health Care Conference on …See details»
Foghorn Therapeutics - Overview, News & Similar companies
Foghorn Therapeutics contact info: Phone number: (617) 586-3100 Website: www.foghorntx.com What does Foghorn Therapeutics do? Foghorn Therapeutics Inc., a clinical-stage …See details»
Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to …
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines …See details»
About - foghorntx.com
Foghorn Therapeutics is a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression.See details»
Foghorn Therapeutics - Company Profile - Tracxn
Foghorn Therapeutics - Developer of therapies for treating cancers, neurological disorders & immunological disorders. Public Company. Raised funding from 3 investors. Foghorn …See details»
Home - foghorntx.com
A New Class of Therapeutics. Foghorn is pioneering a new class of medicines that treat serious disease by correcting abnormal gene expression. These precision therapeutic candidates …See details»
Foghorn Therapeutics - Craft
Oct 29, 2024 Foghorn Therapeutics has 3 employees across 2 locations and $34.16 m in annual revenue in FY 2023. See insights on Foghorn Therapeutics including office locations, …See details»
Foghorn® Therapeutics Expands Leadership Team with Two C …
Sep 16, 2019 Fanny Cavalié, Foghorn Therapeutics +1 (617) 238-4954 fcavalie@foghorntx.com. Greg Kelley, Ogilvy +1 (617) 761-6724 gregory.kelley@ogilvy.com. …See details»
Work Here - foghorntx.com
Collaborate to innovate “This is the same boat everybody is in. It's hard. There's a reason it’s hard. And we're at the forefront of doing this work.”See details»
Foghorn Therapeutics Announces Change to Board of Directors
Aug 31, 2022 Foghorn Congratulates Co-Founder Cigall Kadoch on HHMI Appointment and Change in Role to Scientific Advisor to the Board. CAMBRIDGE, Mass., Aug. 31, 2022 …See details»
Foghorn Therapeutics (USA) Funding: $221M - Medical Startups
Apr 24, 2025 Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express, and when, where, and in what...See details»
Foghorn Therapeutics Announces Chief Medical Officer
Aug 8, 2023 Visit our website at www.foghorntx.com for more information on the company, and follow us on X (formally Twitter) and LinkedIn. Forward-Looking Statements This press release …See details»
Foghorn Therapeutics - Work in biotech
Foghorn Therapeutics’ Gene Traffic Control platform is designed to target and modulate the chromatin regulatory system. Components of the chromatin regulatory system are synthesized …See details»
Foghorn Therapeutics Announces Chief Medical Officer Succession
Aug 8, 2023 Visit our website at www.foghorntx.com for more information on the company, and follow us on X (formally Twitter) and LinkedIn. Forward-Looking Statements This press release …See details»